Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions (OVANCON)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00587327
First received: December 21, 2007
Last updated: April 16, 2013
Last verified: April 2013
  Purpose
The main purpose of this clinical research trial was to evaluate the effects of barusiban and atosiban compared to placebo on luteal phase uterine contractions in oocyte donors supplemented with progesterone.

Condition Intervention Phase
In Vitro Fertilisation (IVF) Treatment.
Drug: Barusiban
Drug: Atosiban
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Study Assessing the Effects of a Selective Oxytocin Antagonist (Barusiban) and a Mixed Oxytocin Antagonist - Vasopressin V1a Antagonist (Atosiban) Administered Intravenously on Luteal Phase Uterine Contractions in Oocyte Donors Supplemented With Vaginal Progesterone

Resource links provided by NLM:


Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Frequency of uterine contractions [ Time Frame: 3h after start of dosing ]

Secondary Outcome Measures:
  • Period, external contractile measure, internal contractile measure and total contractile measure of uterine contractions [ Time Frame: 3h after start of dosing ]
  • Frequency, period, external contractile measure, internal contractile measure and total contractile measure of uterine contractions [ Time Frame: 5 min, 15 min, 30 min, 1h, 1h 30 min, 2h, and 2h 30 min after start of dosing ]
  • Frequency, period, external contractile measure, internal contractile measure and total contractile measure of uterine contractions [ Time Frame: 5 min, 30 min, and 1h after mock embryo transfer ]
  • Frequency, period, external contractile measure, internal contractile measure and total contractile measure of uterine contractions [ Time Frame: 30 min and 1h post-dosing and on Day OR +5 ]
  • Inter-subendometrial space [ Time Frame: 5 min, 15 min, 30 min, 1h, 1h 30 min, 2h, 2h 30 min, and 3h after start of dosing, at 5 min, 30 min, and 1h after mock embryo transfer, at 30 min and 1h post-dosing and on Day OR +5 ]
  • Pharmacokinetic parameters of barusiban and atosiban [ Time Frame: 2 days after oocyte retrieval (Day OR +2, sampling throughout the day) and 5 days after oocyte retrieval (Day OR +5, one sampling) ]
  • Population pharmacokinetic / pharmacodynamic model [ Time Frame: 30 min and 3h after start of dosing ]

Enrollment: 125
Study Start Date: November 2007
Study Completion Date: September 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Barusiban Drug: Barusiban
Solution for IV treatment. Bolus and infusion for 4 hours
Experimental: Atosiban Drug: Atosiban
Solution for IV administration. Bolus and infusion for 4 hours
Placebo Comparator: Placebo Drug: Placebo
Saline solution for IV administration. Bolus and infusion for 4 hours.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria
Participants eligible for this trial were oocyte donors 18-35 years of age, who had undergone controlled ovarian hyperstimulation in the long GnRH agonist protocol or the multiple-dose or single-dose GnRH antagonist protocols, had received hCG (≥ 5,000 IU urinary hCG or 250 μg recombinant hCG) for triggering of final follicular maturation and had undergone oocyte retrieval with a yield of ≥ 6 cumulus-oocyte-complexes. Participants had given signed informed consent, were generally healthy and with a body mass index (BMI) of 18.5-29.9 kg/m2. Participants were excluded in case of endometriosis stage I-IV or uterine pathology. Participants were willing to not have intake of alcoholic beverages during the trial, to not have sexual intercourse during the trial, and to either maintain sexual abstinence or use a highly effective method of contraception from end-of-trial till onset of next menses.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00587327

Locations
Belgium
UZ Brussel, Center for Reproductive Medicine
Brussels, Belgium
Czech Republic
Institute for Reproductive Medicine and Endocrinology
Pilsen, Czech Republic, 30177
ISCARE IVF a.s.
Prague, Czech Republic
Spain
Institut Universitari Dexeus
Barcelona, Spain, 08028
IVI Madrid
Madrid, Spain, 28035
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00587327     History of Changes
Other Study ID Numbers: FE200440 CS09 
Study First Received: December 21, 2007
Last Updated: April 16, 2013

Additional relevant MeSH terms:
Oxytocin
Atosiban
Vasopressins
Arginine Vasopressin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs
Hemostatics
Coagulants
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Tocolytic Agents

ClinicalTrials.gov processed this record on January 23, 2017